Last update Oct. 15, 2016

Ceftizoxime Sodium

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Third-generation cephalosporin for injection or parenteral administration.

Like most cephalosporins for which data are available, excretion occurs in breast milk in very small amount and it is clinically insignificant (Takase 1980, Motomura 1980, Gerding 1982, Matsuda 1984).

Cephalosporins are widely used in the Pediatric practice with a good tolerance, even in the neonatal period, so it is very unlikely that in small amounts through milk would be a cause of problems in the infant.

Be aware of the possibility of false negative results of cultures in febrile infants whose mothers are taking antibiotics as well as the possibility of gastroenteritis (Ito 1993) by altering the intestinal flora.

Alternatives

We do not have alternatives for Ceftizoxime Sodium since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Ceftizoxime Sodium in other languages or writings:

Group

Ceftizoxime Sodium belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ceftizoxime Sodium in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. < 5 %
Molecular weight 405 daltons
Protein Binding 30 %
VD 0.35 - 0.5 l/Kg
Tmax 1 hours
T½ 1.7 hours
Theoretical Dose 0.0015 - 0.12 mg/Kg/d
Relative Dose 0.009 - 0.7 %

References

  1. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  2. Fulton B, Moore LL. Antiinfectives in breastmilk. Part I: Penicillins and cephalosporins. J Hum Lact. 1992 Abstract
  3. Ito K, Izumi K, Takagi H, Yokoyama Y, Tamaya T, Baba Y, Hayasaki M. [Pharmacokinetic and clinical studies of ceftizoxime in obstetrical and gynecological field (2)]. Jpn J Antibiot. 1988 Abstract
  4. Cho N, Fukunaga K, Kunii K, Tezuka K, Kobayashi I. [Studies of ceftizoxime in perinatal period]. Jpn J Antibiot. 1988 Abstract
  5. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol. 1984;5(2):57-60. Abstract
  6. Gerding DN, Peterson LR. Comparative tissue and extravascular fluid concentrations of ceftizoxime. J Antimicrob Chemother. 1982 Abstract
  7. akase Z, Inoue K, Shirafuji H et al. Clinical and laboratory studies on ceftizoxime (CZX) in the field of obstetrics and gynecology. Chemotherapy (Tokyo). 1980;28 (Suppl 5):863-73. 1980
  8. Motomura R, Kohno M, Mori H, Yamabe T. Basic and clinical studies of ceftizoxime in obstetrics and gynecology. Chemotherapy (Tokyo) 1980;28(Suppl 5):888–99. 1980

Total visits

4,881

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM